Overview of Rheumatoid Arthritis: Symptoms, Causes, and Treatments

Authors

  • Jiaying Zheng

DOI:

https://doi.org/10.61173/1whq7r25

Keywords:

Rheumatoid Arthritis, RA, Pathogenesis of RA, Treatments, Disease-modifying Antirheumatic Drugs, DMARDs, methotrexate, Non-steroidal Anti-inflammato-ry Drugs, NSAIDs, naproxen, structure, functions

Abstract

Rheumatoid arthritis (RA) is a long-term disease with the characteristics of inflammation throughout the body. Patients with RA typically experience joint pain and other complications. The pathogenesis of RA is complicated, with the factors of genes, environment, and autoantibodies. Rheumatoid arthritis can lead to more serious consequences in the other parts of the body without treatments. Hence, the drugs for the treatment of RA are necessary. Nowadays, there are four main types of drugs: non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), and biological agents. This article will mainly discuss the pathogenesis of RA and compare two types of drugs, NSAIDs, and DMARDs, with one selected for each.

References

[1] S. Pirmardvand Chegini, J. Varshosaz and S. Taymouri, Artificial Cells, Nanomedicine, and Biotechnology, 2018, 46, 502–514.

[2] F. Wu, J. Gao, J. Kang, X. Wang, Q. Niu, J. Liu and L. Zhang, Front. Immunol., 2021, 12, 750753.

[3] S. Thakur, B. Riyaz, A. Patil, A. Kaur, B. Kapoor and V. Mishra, Biomedicine & Pharmacotherapy, 2018, 106, 1011– 1023.

[4] M. Zamanpoor, Clinical Genetics, 2019, 95, 547–557.

[5] D. Wu, Y. Luo, T. Li, X. Zhao, T. Lv, G. Fang, P. Ou, H. Li, X. Luo, A. Huang and Y. Pang, Front. Immunol., 2022, 13, 1051082.

[6] W. Zou, Y. Fang, D. Xu and Y. Zhu, Arch Med Sci, DOI:10.5114/aoms/162629.

[7] D. Aletaha and H. Radner, in Oxford Textbook of Rheumatoid Arthritis, Oxford University Press, 2020, pp. 13–22.

[8] D. Aletaha, T. Neogi, A. J. Silman, J. Funovits, D. T. Felson, C. O. Bingham, N. S. Birnbaum, G. R. Burmester, V. P. Bykerk, M. D. Cohen, B. Combe, K. H. Costenbader, M. Dougados, P. Emery, G. Ferraccioli, J. M. W. Hazes, K. Hobbs, T. W. J. Huizinga, A. Kavanaugh, J. Kay, T. K. Kvien, T. Laing, P. Mease, H. A. Ménard, L. W. Moreland, R. L. Naden, T. Pincus, J. S. Smolen, E. Stanislawska‐Biernat, D. Symmons, P. P. Tak, K. S. Upchurch, J. Vencovský, F. Wolfe and G. Hawker, Arthritis & Rheumatism, 2010, 62, 2569–2581.

[9] Rheumatoid Arthritis- Symptoms, Types, Pathogenesis, Diagnosis, Medications, Prevention, https://sciencevivid.com/ rheumatoid-arthritis-symptoms-types-pathogenesis-diagnosismedications-prevention/, (accessed 29 July 2024).

[10] A. N. Theofilopoulos, D. H. Kono and R. Baccala, Nat Immunol, 2017, 18, 716–724.

[11] T. W. J. Huizinga, in Oxford Textbook of Rheumatoid Arthritis, Oxford University Press, 2020, pp. 65–72.

[12] H. U. Scherer, D. Van Der Woude and R. E. M. Toes, Nat Rev Rheumatol, 2022, 18, 371–383.

[13] A.-L. Mueller, Z. Payandeh, N. Mohammadkhani, S. M. H. Mubarak, A. Zakeri, A. Alagheband Bahrami, A. Brockmueller and M. Shakibaei, Cells, 2021, 10, 3017.

[14] J. S. Smolen, D. Aletaha and I. B. McInnes, The Lancet, 2016, 388, 2023–2038.

[15] D. Aletaha and J. S. Smolen, JAMA, 2018, 320, 1360.

[16] A. Finckh, B. Gilbert, B. Hodkinson, S.-C. Bae, R. Thomas, K. D. Deane, D. Alpizar- Rodriguez and K. Lauper, Nat Rev Rheumatol, DOI:10.1038/s41584-022-00827-y.

[17] D. L. Scott, in Oxford Textbook of Rheumatoid Arthritis, Oxford University Press, 2020, pp. 355–370.

[18] Y. Bedoui, X. Guillot, J. Sélambarom, P. Guiraud, C. Giry, M. C. Jaffar-Bandjee, S. Ralandison and P. Gasque, IJMS, 2019, 20, 5023.

[19] S. F. Ling and J. Bluett, Pharmacogenomics, 2020, 21, 3–6.

[20] C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Advanced Drug Delivery Reviews, 1997, 23, 3–25.

[21] R. Then, in xPharm: The Comprehensive Pharmacology Reference, Elsevier, 2007, pp. 1–7. Dean&Francis Jiaying Zheng

[22] B. Friedman and B. Cronstein, Joint Bone Spine, 2019, 86, 301–307.

[23] W. Wang, H. Zhou and L. Liu, European Journal of Medicinal Chemistry, 2018, 158, 502–516.

[24] S. C. Howard, J. McCormick, C.-H. Pui, R. K. Buddington and R. D. Harvey, The Oncologist, 2016, 21, 1471–1482.

[25] A.-M. Schjerning, P. McGettigan and G. Gislason, Nat Rev Cardiol, 2020, 17, 574–584.

[26] M. D. Russell and N. Sofat, in Oxford Textbook of Rheumatoid Arthritis, Oxford University Press, 2020, pp. 331– 338.

[27] H. S. Smith, in Encyclopedia of the Neurological Sciences, Elsevier, 2014, pp. 610–613.

[28] M.-W. Ha and S.-M. Paek, Molecules, 2021, 26, 4792.

[29] M. Valentovic, in xPharm: The Comprehensive Pharmacology Reference, Elsevier, 2007, pp. 1–6.

[30] A. Hughes, F. R. Saunders and H. M. Wallace, Toxicol. Res., 2012, 1, 108.

[31] Brutzkus JC, Shahrokhi M, Varacallo M. Naproxen. [Updated 2023 Aug 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK525965/, (accessed 29 July 2024).

[32] A. Hughes, N. I. Smith and H. M. Wallace, Biochemical Journal, 2003, 374, 481–488.

Downloads

Published

2025-07-06

Issue

Vol. 3 No. 3 (2025): Volume 3, Issue 3

Section

Articles

License

Copyright (c) 2025 by the authors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.